Compare Organon & Co. Common Stock (OGN) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Skyworks Solutions Inc — how do they compare? Organon & Co. Common Stock trades at $13.73 (market cap $3.61B), while Skyworks Solutions Inc trades at $76.44 (market cap $18.08B). The key difference: Skyworks Solutions Inc is far larger — about 5× Organon & Co. Common Stock's market cap, and Skyworks Solutions Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Skyworks Solutions Inc for 50 Days on average.
| OGN | SWKS | |
|---|---|---|
Market Cap | $3.61B | $18.08B |
Volume | 1,808,049 | 5,128,915 |
Sector | Health | Technology |
52-Week High | $13.81 | $91.45 |
52-Week Low | $5.70 | $52.50 |
Typical Hold Time | 0 Days | 50 Days |
Enterprise Value | $11.03B | $17.96B |
Dividend Yield | 0.58% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Skyworks Solutions (SWKS) trades at $76.56, up 2.49% with a bearish technical signal despite recent earnings beats. The stock shows declining revenue and profit margins over recent years but maintains strong analyst support with 60% buy ratings. The pending Qorvo merger represents a significant catalyst, with regulatory clearances obtained and potential for $500 million in synergies. Current valuation metrics include a P/E of 39.68 and P/S of 2.87.
The merger with Qorvo offers substantial growth potential through expanded scale and market diversification, though integration risks and declining financial metrics warrant caution. With the current price below the $79.70 consensus target, upside exists if merger benefits materialize, but investors face execution risk and competitive pressures in the semiconductor sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
